Ruggero De Maria

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8260738/publications.pdf

Version: 2024-02-01

281	30,727	9756	4978
papers	citations	73 h-index	167 g-index

284	284	284	41176
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	5.0	4,036
2	Identification and expansion of human colon-cancer-initiating cells. Nature, 2007, 445, 111-115.	13.7	3,690
3	Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death and Differentiation, 2008, 15, 504-514.	5.0	1,511
4	Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature, 2010, 468, 824-828.	13.7	1,235
5	The miR-15aâ€“miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nature Medicine, 2008, 14, 1271-1277.	15.2	919
6	Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death and Differentiation, 2015, 22, 58-73.	5.0	811
7	CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer Metastasis. Cell Stem Cell, 2014, 14, 342-356.	5.2	617
8	Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death and Differentiation, 2009, 16, 1093-1107.	5.0	599
9	Cancer stem cell definitions and terminology: the devil is in the details. Nature Reviews Cancer, 2012, 12, 767-775.	12.8	599
10	Chemotherapy resistance of glioblastoma stem cells. Cell Death and Differentiation, 2006, 13, 1238-1241.	5.0	578
11	Potential Involvement of Fas and Its Ligand in the Pathogenesis of Hashimoto's Thyroiditis. Science, 1997, 275, 960-963.	6.0	557
12	Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase.. Journal of Experimental Medicine, 1994, 180, 1547-1552.	4.2	526
13	KDR Receptor: A Key Marker Defining Hematopoietic Stem Cells. Science, 1999, 285, 1553-1558.	6.0	449
14	The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Trends in Immunology, 1994, 15, 479-483.	7.5	415
15	Requirement for GD3 Ganglioside in CD95- and Ceramide-Induced Apoptosis. Science, 1997, 277, 1652-1655.	6.0	404
16	Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature, 1999, 401, 489-493.	13.7	369
17	Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Molecular Cancer, 2019, 18, 70.	7.9	361
18	Colorectal Cancer Stem Cells: From the Crypt to the Clinic. Cell Stem Cell, 2014, 15, 692-705.	5.2	340

#	Article	IF	Citations
19	Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme. Clinical Cancer Research, 2008, 14, 8205-8212.	3.2	327
20	Epithelialâ€“mesenchymal transition: a new target in anticancer drug discovery. Nature Reviews Drug Discovery, 2016, 15, 311-325.	21.5	290
21	TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene, 2015, 34, 681-690.	2.6	287
22	DNA Damage in Stem Cells. Molecular Cell, 2017, 66, 306-319.	4.5	259
23	Autoimmune thyroid disease: new models of cell death in autoimmunity. Nature Reviews Immunology, 2002, 2, 195-204.	10.6	236
24	Nitric Oxide Primes Pancreatic Î² Cells for Fas-mediated Destruction in Insulin-dependent Diabetes Mellitus. Journal of Experimental Medicine, 1997, 186, 1193-1200.	4.2	234
25	Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene, 2011, 30, 4231-4242.	2.6	221
26	The Inhibition of the Highly Expressed Mir-221 and Mir-222 Impairs the Growth of Prostate Carcinoma Xenografts in Mice. PLoS ONE, 2008, 3, e4029.	1.1	219
27	Bone Morphogenetic Protein 4 Induces Differentiation of Colorectal Cancer Stem Cells and Increases Their Response to Chemotherapy in Mice. Gastroenterology, 2011, 140, 297-309.e6.	0.6	202
28	Tumorigenic and Metastatic Activity of Human Thyroid Cancer Stem Cells. Cancer Research, 2010, 70, 8874-8885.	0.4	197
29	Colon cancer stem cells. Journal of Molecular Medicine, 2009, 87, 1097-1104.	1.7	193
30	Cancer Stem Cells and Chemosensitivity. Clinical Cancer Research, 2011, 17, 4942-4947.	3.2	181
31	Triggering of human monocyte activation through CD69, a member of the natural killer cell gene complex family of signal transducing receptors.. Journal of Experimental Medicine, 1994, 180, 1999-2004.	4.2	162
32	Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene, 2013, 32, 4806-4813.	2.6	159
33	Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death and Differentiation, 2012, 19, 768-778.	5.0	157
34	Acidic Sphingomyelinase (ASM) Is Necessary for Fas-induced GD3 Ganglioside Accumulation and Efficient Apoptosis of Lymphoid Cells. Journal of Experimental Medicine, 1998, 187, 897-902.	4.2	155
35	DNA Damage Repair Pathways in Cancer Stem Cells. Molecular Cancer Therapeutics, 2012, 11, 1627-1636.	1.9	147
36	IL-4 Protects Tumor Cells from Anti-CD95 and Chemotherapeutic Agents via Up-Regulation of Antiapoptotic Proteins. Journal of Immunology, 2004, 172, 5467-5477.	0.4	142

#	Article	IF	Citations
37	Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nature Immunology, 2000, 1, 483-488.	7.0	139
38	MicroRNAs and prostate cancer. Endocrine-Related Cancer, 2010, 17, F1-F17.	1.6	139
39	The Hippo pathway in normal development and cancer. , 2018, 186, 60-72.		134
40	Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis.. Journal of Clinical Investigation, 1996, 98, 2616-2622.	3.9	129
41	Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene, 2010, 29, 4625-4635.	2.6	125
42	Endogenous activation of metabotropic glutamate receptors supports the proliferation and survival of neural progenitor cells. Cell Death and Differentiation, 2005, 12, 1124-1133.	5.0	124
43	Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited. Neoplasia, 2011, 13, 1113-IN6.	2.3	115
44	A microRNA code for prostate cancer metastasis. Oncogene, 2016, 35, 1180-1192.	2.6	115
45	Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes. A potential role for the acidic sphingomyelinase pathway in normal immunoregulation.. Journal of Clinical Investigation, 1996, 97, 316-322.	3.9	113
46	Autocrine Production of Interleukin-4 and Interleukin-10 Is Required for Survival and Growth of Thyroid Cancer Cells. Cancer Research, 2006, 66, 1491-1499.	0.4	110
47	Caspase activation without death. Cell Death and Differentiation, 1999, 6, 1075-1080.	5.0	109
48	PTEN Tumor-Suppressor: The Dam of Stemness in Cancer. Cancers, 2019, 11, 1076.	1.7	108
49	Transferrin Receptor 2 Is Frequently and Highly Expressed in Glioblastomas. Translational Oncology, 2010, 3, 123-134.	1.7	106
50	Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. OncoImmunology, 2017, 6, e1314424.	2.1	106
51	Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases. Cell Death and Disease, 2019, 10, 201.	2.7	105
52	Ceramide Inhibits Antigen Uptake and Presentation by Dendritic Cells. Journal of Experimental Medicine, 1996, 184, 2411-2416.	4.2	104
53	Fasâ€“FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. Trends in Immunology, 1998, 19, 121-125.	7.5	104
54	Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. Journal of Neuroinflammation, 2011, 8, 32.	3.1	102

#	Article	IF	Citations
55	Absence of Caspase 8 and High Expression of PED Protect Primitive Neural Cells from Cell Death. Journal of Experimental Medicine, 2004, 200, 1257-1266.	4.2	101
56	TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. Carcinogenesis, 2010, 31, 794-803.	1.3	101
57	Integrin Î±7 Is a Functional Marker and Potential Therapeutic Target in Glioblastoma. Cell Stem Cell, 2017, 21, 35-50.e9.	5.2	101
58	Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Research, 2003, 63, 6784-90.	0.4	101
59	Targeting apoptosis pathways in cancer stem cells. Cancer Letters, 2013, 332, 374-382.	3.2	100
60	Mesenchymal differentiation of glioblastoma stem cells. Cell Death and Differentiation, 2008, 15, 1491-1498.	5.0	97
61	CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of typeâ€„I and typeâ€„II cells. European Journal of Immunology, 2004, 34, 1930-1940.	1.6	95
62	BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelialâ€“mesenchymal transition. Oncogene, 2013, 32, 1843-1853.	2.6	94
63	Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. Cell Death and Differentiation, 2014, 21, 1877-1888.	5.0	90
64	Î²-Amyloid-Induced Synthesis of the Ganglioside Gd3 Is a Requisite for Cell Cycle Reactivation and Apoptosis in Neurons. Journal of Neuroscience, 2002, 22, 3963-3968.	1.7	89
65	Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death and Differentiation, 2014, 21, 774-782.	5.0	86
66	Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma. Oncogene, 2017, 36, 4641-4652.	2.6	86
67	Discovery of Salermide-Related Sirtuin Inhibitors: Binding Mode Studies and Antiproliferative Effects in Cancer Cells Including Cancer Stem Cells. Journal of Medicinal Chemistry, 2012, 55, 10937-10947.	2.9	84
68	Multiple Members of the TNF Superfamily Contribute to IFN-Î³-Mediated Inhibition of Erythropoiesis. Journal of Immunology, 2005, 175, 1464-1472.	0.4	81
69	Inhibition of DNA Methylation Sensitizes Glioblastoma for Tumor Necrosis Factorâ€“Related Apoptosis-Inducing Ligandâ€“Mediated Destruction. Cancer Research, 2005, 65, 11469-11477.	0.4	81
70	Apoptosis in normal and cancer stem cells. Critical Reviews in Oncology/Hematology, 2008, 66, 42-51.	2.0	80
71	Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer, 2011, 117, 162-174.	2.0	80
72	Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Review of Vaccines, 2016, 15, 1327-1336.	2.0	79

#	Article	IF	Citations
73	Continuousin vivo activation and transient hyporesponsiveness to TcR/CD3 triggering of human gut lamina propria lymphocytes. European Journal of Immunology, 1993, 23, 3104-3108.	1.6	77
74	Chemotherapy-Induced Thrombocytopenia Derives from the Selective Death of Megakaryocyte Progenitors and Can Be Rescued by Stem Cell Factor. Cancer Research, 2007, 67, 4767-4773.	0.4	77
75	The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. Expert Reviews in Molecular Medicine, 2015, 17, e14.	1.6	75
76	Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome. Scientific Reports, 2016, 6, 21557.	1.6	75
77	The transient receptor potential vanilloidâ€2 cation channel impairs glioblastoma stemâ€like cell proliferation and promotes differentiation. International Journal of Cancer, 2012, 131, E1067-77.	2.3	71
78	Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment. Oncogene, 2008, 27, 358-365.	2.6	70
79	Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. International Journal of Cancer, 2012, 131, 2197-2203.	2.3	70
80	Colon cancer stem cells. Gut, 2007, 57, 538-548.	6.1	64
81	A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells. Cell Death and Differentiation, 2012, 19, 1644-1654.	5.0	64
82	CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. Gut, 2018, 67, 903-917.	6.1	64
83	Cancer stem cells: perspectives for therapeutic targeting. Cancer Immunology, Immunotherapy, 2015, 64, 91-97.	2.0	63
84	Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma. Journal of Thoracic Oncology, 2019, 14, 1924-1934.	0.5	60
85	Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening. Frontiers in Immunology, 2020, 11, 2166.	2.2	60
86	NF-Î²B protects BehÃ§et's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis and Rheumatism, 2005, 52, 2179-2191.	6.7	59
87	Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells. Endocrine-Related Cancer, 2010, 17, 823-833.	1.6	58
88	Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Cell Death and Disease, 2014, 5, e1223-e1223.	2.7	57
89	The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response. Neuro-Oncology, 2017, 19, 1097-1108.	0.6	56
90	A pre-existing population of ZEB2+ quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 2.	3.5	56

#	Article	IF	Citations
91	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. Journal of Molecular Medicine, 2012, 90, 667-679.	1.7	54
92	Proliferation State and Polo-Like Kinase1 Dependence of Tumorigenic Colon Cancer Cells. Stem Cells, 2012, 30, 1819-1830.	1.4	53
93	Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death and Differentiation, 2013, 20, 396-407.	5.0	53
94	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget, 2017, 8, 56921-56931.	0.8	53
95	Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins. Blood, 2003, 102, 87-93.	0.6	51
96	Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. Molecular Cancer, 2014, 13, 230.	7.9	51
97	Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. Blood, 2006, 107, 3495-3502.	0.6	50
98	Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. Cancer Treatment Reviews, 2013, 39, 525-533.	3.4	50
99	Dynamic regulation of the cancer stem cell compartment by Cripto-1 in colorectal cancer. Cell Death and Differentiation, 2015, 22, 1700-1713.	5.0	50
100	Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. Oncotarget, 2016, 7, 11332-11348.	0.8	49
101	Proteasome Inhibitors Synergize with Tumor Necrosis Factor-Related Apoptosis-Induced Ligand to Induce Anaplastic Thyroid Carcinoma Cell Death. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1938-1942.	1.8	48
102	Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance. Stem Cells Translational Medicine, 2016, 5, 511-523.	1.6	48
103	Hippo pathway and breast cancer stem cells. Critical Reviews in Oncology/Hematology, 2016, 99, 115-122.	2.0	48
104	New models for cancer research: human cancer stem cell xenografts. Current Opinion in Pharmacology, 2010, 10, 380-384.	1.7	47
105	MicroRNA as New Tools for Prostate Cancer Risk Assessment and Therapeutic Intervention: Results from Clinical Data Set and Patientsâ€™ Samples. BioMed Research International, 2014, 2014, 1-17.	0.9	46
106	Cancer stem cells: at the forefront of personalized medicine and immunotherapy. Current Opinion in Pharmacology, 2017, 35, 1-11.	1.7	46
107	PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells. Gut, 2022, 71, 119-128.	6.1	46
108	Control of erythroid cell production via caspase-mediated cleavage of transcription factor SCL/Tal-1. Cell Death and Differentiation, 2003, 10, 905-913.	5.0	45

#	Article	IF	Citations
109	Defective T cell receptor/CD3 complex signaling in human type I diabetes. European Journal of Immunology, 1994, 24, 999-1002.	1.6	44
110	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Scientific Reports, 2017, 7, 43013.	1.6	44
111	Presence of anaplastic lymphoma kinase in inflammatory breast cancer. SpringerPlus, 2013, 2, 497.	1.2	43
112	Aloe-emodin exerts a potent anticancer and immunomodulatory activity on BRAF-mutated human melanoma cells. European Journal of Pharmacology, 2015, 762, 283-292.	1.7	43
113	Functional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL. PLoS ONE, 2010, 5, e13552.	1.1	42
114	Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. Cancer, 2013, 119, 1004-1012.	2.0	42
115	Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. Cell Death and Disease, 2015, 6, e1850-e1850.	2.7	42
116	Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells. American Journal of Pathology, 2017, 187, 1633-1647.	1.9	42
117	miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal. Oncotarget, 2015, 6, 37241-37256.	0.8	42
118	Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells. Neuropharmacology, 2008, 55, 568-576.	2.0	40
119	AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. Leukemia, 2013, 27, 1019-1027.	3.3	40
120	Sphere-forming cell subsets with cancer stem cell properties in human musculoskeletal sarcomas. International Journal of Oncology, 2013, 43, 95-102.	1.4	40
121	Influence of local environment on the differentiation of neural stem cells engrafted onto the injured spinal cord. Neurological Research, 2006, 28, 488-492.	0.6	39
122	Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells. European Respiratory Journal, 2021, 58, 2100908.	3.1	39
123	Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery. Nature Communications, 2021, 12, 5006.	5.8	38
124	Erythropoietin Activates Cell Survival Pathways in Breast Cancer Stemâ€“like Cells to Protect Them from Chemotherapy. Cancer Research, 2013, 73, 6393-6400.	0.4	37
125	A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors. Cell Death and Disease, 2019, 10, 529.	2.7	37
126	Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity. BMC Cancer, 2008, 8, 212.	1.1	36

#	Article	IF	Citations
127	EGFR Inhibition Abrogates Leiomyosarcoma Cell Chemoresistance through Inactivation of Survival Pathways and Impairment of CSC Potential. PLoS ONE, 2012, 7, e46891.	1.1	36
128	MicroRNAs and Prostate Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 253-261.	1.0	35
129	Role of autophagy in the maintenance and function of cancer stem cells. International Journal of Developmental Biology, 2015, 59, 95-108.	0.3	35
130	C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition. Oncogene, 2017, 36, 3718-3728.	2.6	35
131	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Oncotarget, 2014, 5, 9619-9625.	0.8	35
132	The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Oncotarget, 2016, 7, 43188-43198.	0.8	35
133	Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Cell Research, 2008, 18, 664-676.	5.7	34
134	Systems Analysis of the NCI-60 Cancer Cell Lines by Alignment of Protein Pathway Activation Modules with â€œ-OMICâ€•Data Fields and Therapeutic Response Signatures. Molecular Cancer Research, 2013, 11, 676-685.	1.5	34
135	Blocking endothelin-1-receptor/Î²-catenin circuit sensitizes to chemotherapy in colorectal cancer. Cell Death and Differentiation, 2017, 24, 1811-1820.	5.0	34
136	MUC1 Oncoprotein Promotes Refractoriness to Chemotherapy in Thyroid Cancer Cells. Cancer Research, 2007, 67, 5522-5530.	0.4	33
137	Thymosin Î²4 targeting impairs tumorigenic activity of colon cancer stem cells. FASEB Journal, 2010, 24, 4291-4301.	0.2	33
138	Benzodeazaoxaflavins as Sirtuin Inhibitors with Antiproliferative Properties in Cancer Stem Cells. Journal of Medicinal Chemistry, 2012, 55, 8193-8197.	2.9	33
139	â€œTriple positiveâ€•early breast cancer: an observational multicenter retrospective analysis of outcome. Oncotarget, 2016, 7, 17932-17944.	0.8	33
140	Defective expression of the apoptosis-inducing CD95 (Fas/APO-1) molecule on T and B cells in IDDM. Diabetologia, 1995, 38, 1449-1454.	2.9	32
141	T-cell activation in HLA-B8,DR3-positive individuals early antigen expression defect in vitro. Human Immunology, 1995, 42, 289-294.	1.2	32
142	Suppressor of Cytokine Signaling 3 Sensitizes Anaplastic Thyroid Cancer to Standard Chemotherapy. Cancer Research, 2009, 69, 6141-6148.	0.4	32
143	Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. Journal of Hematology and Oncology, 2015, 8, 53.	6.9	32
144	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. Journal of Experimental and Clinical Cancer Research, 2020, 39, 279.	3.5	32

#	Article	IF	Citations
145	Replication stress response in cancer stem cells as a target for chemotherapy. Seminars in Cancer Biology, 2018, 53, 31-41.	4.3	31
146	CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin. IScience, 2021, 24, 102664.	1.9	31
147	An organoid model of colorectal circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile. Journal of Experimental and Clinical Cancer Research, 2022, 41, 86.	3.5	31
148	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. OncoImmunology, 2016, 5, e1160187.	2.1	30
149	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. International Journal of Cancer, 2017, 140, 2587-2595.	2.3	30
150	A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. Cancer Biology and Therapy, 2019, 20, 192-200.	1.5	30
151	Downregulation of thymosin Î²4 in neural progenitor grafts promotes spinal cord regeneration. Journal of Cell Science, 2009, 122, 4195-4207.	1.2	29
152	Fas-FasL in Hashimoto's thyroiditis. Journal of Clinical Immunology, 2001, 21, 19-23.	2.0	28
153	Antitumor Activity of Bortezomib Alone and in Combination with Trail in Human Acute Myeloid Leukemia. Acta Haematologica, 2008, 120, 19-30.	0.7	28
154	KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. Journal of Thoracic Oncology, 2021, 16, 2065-2077.	0.5	28
155	Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells. Oncotarget, 2015, 6, 16926-16938.	0.8	28
156	Potential role of APRIL as autocrine growth factor for megakaryocytopoiesis. Blood, 2004, 104, 3169-3172.	0.6	27
157	¹H NMR spectroscopy of glioblastoma stemâ€like cells identifies alphaâ€aminoadipate as a marker of tumor aggressiveness. NMR in Biomedicine, 2015, 28, 317-326.	1.6	27
158	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Journal of Experimental and Clinical Cancer Research, 2018, 37, 140.	3.5	27
159	A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 373.	3.5	27
160	miR-663 sustains NSCLC by inhibiting mitochondrial outer membrane permeabilization (MOMP) through PUMA/BBC3 and BTG2. Cell Death and Disease, 2018, 9, 49.	2.7	26
161	Study of T-cell activation in Type I diabetic patients and pre-Type I diabetic subjects by cytometric analysis: Antigen expression defectin vitro. Journal of Clinical Immunology, 1993, 13, 68-78.	2.0	25
162	Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line. Cell Death and Differentiation, 2006, 13, 61-74.	5.0	24

#	Article	IF	Citations
163	Prevention of Chemotherapy-Induced Anemia and Thrombocytopenia by Constant Administration of Stem Cell Factor. Clinical Cancer Research, 2011, 17, 6185-6191.	3.2	24
164	¹H NMR detects different metabolic profiles in glioblastoma stemâ€like cells. NMR in Biomedicine, 2014, 27, 129-145.	1.6	24
165	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. Breast Cancer Research and Treatment, 2014, 148, 73-80.	1.1	24
166	Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. Journal of Experimental and Clinical Cancer Research, 2016, 35, 62.	3.5	24
167	Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant. Oncogene, 2020, 39, 987-1003.	2.6	24
168	Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture. Frontiers in Immunology, 2020, 11, 565631.	2.2	24
169	The Notch2â€“Jagged1 interaction mediates stem cell factor signaling in erythropoiesis. Cell Death and Differentiation, 2011, 18, 371-380.	5.0	23
170	Cancer stem cells as a potential therapeutic target in thyroid carcinoma. Oncology Letters, 2016, 12, 2254-2260.	0.8	23
171	Zika virus infection induces MiR34c expression in glioblastoma stem cells: new perspectives for brain tumor treatments. Cell Death and Disease, 2019, 10, 263.	2.7	23
172	Normal vs cancer thyroid stem cells: the road to transformation. Oncogene, 2016, 35, 805-815.	2.6	22
173	Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. Cancer Biology and Therapy, 2017, 18, 339-346.	1.5	22
174	Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patientâ€derived primary and metastatic lung cancer cells. International Journal of Cancer, 2018, 143, 88-99.	2.3	22
175	Therapeutic Targeting of Cancer Stem Cells. Frontiers in Oncology, 2011, 1, 10.	1.3	22
176	Defective Expression of CD95 (FAS/APO-1) Molecule Suggests Apoptosis Impairment of T and B Cells in HLA-B8, DR3-Positive Individuals. Human Immunology, 1997, 55, 39-45.	1.2	21
177	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptorâ€positive, advanced breast cancer: A realâ€world experience. Journal of Cellular Physiology, 2019, 234, 7708-7717.	2.0	21
178	KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub. Journal of Thoracic Oncology, 2022, 17, 751-757.	0.5	21
179	Low bcl-2 expression and increased spontaneous apoptosis in T-lymphocytes from newly-diagnosed IDDM patients. Diabetologia, 1995, 38, 953-958.	2.9	20
180	Activation of Fas receptor is required for the increased formation of the disialoganglioside GD3 in cultured cerebellar granule cells committed to apoptotic death. Neuroscience, 2004, 126, 889-898.	1.1	20

#	Article	IF	Citations
181	Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations. Clinical and Experimental Metastasis, 2013, 30, 309-316.	1.7	20
182	Micro-Economics of Apoptosis in Cancer: ncRNAs Modulation of BCL-2 Family Members. International Journal of Molecular Sciences, 2018, 19, 958.	1.8	20
183	Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer. Cell Death and Disease, 2021, 12, 636.	2.7	20
184	Nobiletin and Xanthohumol Sensitize Colorectal Cancer Stem Cells to Standard Chemotherapy. Cancers, 2021, 13, 3927.	1.7	20
185	Fas-FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. Trends in Immunology, 1998, 19, 121-125.	7.5	19
186	Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood, 2009, 113, 1522-1525.	0.6	19
187	Functional Role and Therapeutic Potential of the Pim-1 Kinase in Colon Carcinoma. Neoplasia, 2013, 15, 773-IN27.	2.3	19
188	Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. Breast Cancer Research and Treatment, 2014, 147, 227-235.	1.1	19
189	HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. Oncogene, 2018, 37, 1369-1385.	2.6	19
190	Measuring Extracellular Vesicles by Conventional Flow Cytometry: Dream or Reality?. International Journal of Molecular Sciences, 2020, 21, 6257.	1.8	19
191	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Realâ€world evidence. Journal of Cellular Physiology, 2020, 235, 7900-7910.	2.0	19
192	Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. Cell Death and Differentiation, 2021, 28, 2060-2082.	5.0	19
193	Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer. Scientific Reports, 2021, 11, 22686.	1.6	19
194	Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. Journal of Experimental and Clinical Cancer Research, 2013, 32, 91.	3.5	18
195	Dual Promoter Usage as Regulatory Mechanism of let-7c Expression in Leukemic and Solid Tumors. Molecular Cancer Research, 2014, 12, 878-889.	1.5	18
196	Establishing tumor cell lines from aggressive telomerase-positive chordomas of the skull base. Journal of Neurosurgery, 2006, 105, 482-484.	0.9	17
197	Androgen receptor and antiandrogen therapy in male breast cancer. Cancer Letters, 2015, 368, 20-25.	3.2	17
198	GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. Journal of Cellular Physiology, 2018, 233, 1396-1401.	2.0	17

#	Article	IF	Citations
199	Renal cancer: new models and approach for personalizing therapy. Journal of Experimental and Clinical Cancer Research, 2018, 37, 217.	3.5	17
200	Human neural progenitor cells display limited cytotoxicity and increased oligodendrogenesis during inflammation. Cell Death and Differentiation, 2007, 14, 876-878.	5.0	16
201	Fas-induced changes in cdc2 and cdk2 kinase activity are not sufficient for triggering apoptosis in HUT-78 cells. Journal of Cellular Biochemistry, 1997, 64, 579-585.	1.2	15
202	Increased phosphoâ€m<scp>TOR</scp> expression in megakaryocytic cells derived from <scp>CD</scp>34+ progenitors of essential thrombocythaemia and myelofibrosis patients. British Journal of Haematology, 2012, 159, 237-240.	1.2	15
203	Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. Journal of Experimental and Clinical Cancer Research, 2015, 34, 26.	3.5	15
204	CD95/CD95L interactions and their role in autoimmunity. Apoptosis: an International Journal on Programmed Cell Death, 2000, 5, 419-424.	2.2	14
205	NF-ÎºB localization in multiple myeloma plasma cells and mesenchymal cells. Leukemia Research, 2011, 35, 52-60.	0.4	14
206	A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology. PLoS ONE, 2015, 10, e0125697.	1.1	14
207	miR-15/miR-16 loss, miR-21 upregulation, or deregulation of their target genes predicts poor prognosis in prostate cancer patients. Molecular and Cellular Oncology, 2016, 3, e1109744.	0.3	14
208	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. Scientific Reports, 2017, 7, 8078.	1.6	14
209	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. Oncotarget, 2015, 6, 42773-42780.	0.8	14
210	Cancer stem cells: are they responsible for treatment failure?. Future Oncology, 2014, 10, 2033-2044.	1.1	13
211	hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. Oncogene, 2016, 35, 887-896.	2.6	13
212	Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. Journal of Translational Medicine, 2018, 16, 22.	1.8	13
213	The secretion and maturation of prosaposin and procathepsin D are blocked in embryonic neural progenitor cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 1480-1489.	1.9	12
214	Not So Lonely at the Top for Cancer Stem Cells. Cell Stem Cell, 2011, 9, 289-290.	5.2	12
215	Biological and clinical implications of cancer stem cells in primary brain tumors. Frontiers in Oncology, 2013, 3, 6.	1.3	12
216	Body mass index modifies the relationship between Î³-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. BMC Cancer, 2017, 17, 101.	1.1	12

#	Article	IF	Citations
217	Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. Oncogenesis, 2018, 7, 55.	2.1	12
218	miR-1285-3p Controls Colorectal Cancer Proliferation and Escape from Apoptosis through DAPK2. International Journal of Molecular Sciences, 2020, 21, 2423.	1.8	12
219	Knockdown of Cancer Testis Antigens Modulates Neural Stem Cell Marker Expression in Glioblastoma Tumor Stem Cells. Journal of Biomolecular Screening, 2010, 15, 830-839.	2.6	11
220	The clinical significance of PD-L1 in advanced gastric cancer is dependent onARID1Amutations and ATM expression. OncoImmunology, 2018, 7, e1457602.	2.1	11
221	CD147 Promotes Cell Small Extracellular Vesicles Release during Colon Cancer Stem Cells Differentiation and Triggers Cellular Changes in Recipient Cells. Cancers, 2020, 12, 260.	1.7	11
222	Repeated Exposure to Subinfectious Doses of SARS-CoV-2 May Promote T Cell Immunity and Protection against Severe COVID-19. Viruses, 2021, 13, 961.	1.5	11
223	DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. PLoS ONE, 2016, 11, e0149872.	1.1	11
224	Knockdown of Ubiquitin Ligases in Glioblastoma Cancer Stem Cells Leads to Cell Death and Differentiation. Journal of Biomolecular Screening, 2012, 17, 152-162.	2.6	10
225	Gene Expression Analysis of PTEN Positive Glioblastoma Stem Cells Identifies DUB3 and Wee1 Modulation in a Cell Differentiation Model. PLoS ONE, 2013, 8, e81432.	1.1	10
226	Alliance Against Cancer, the network of Italian cancer centers bridging research and care. Journal of Translational Medicine, 2015, 13, 360.	1.8	10
227	Lowâ€intensity pulsed ultrasound affects growth, differentiation, migration, and epithelialâ€toâ€mesenchymal transition of colorectal cancer cells. Journal of Cellular Physiology, 2020, 235, 5363-5377.	2.0	10
228	Analysis of Tâ€Lymphocyte Subsets After Phytohemagglutinin Stimulation in Normal and Type 1 Diabetic Mothers and Their Infants. American Journal of Reproductive Immunology, 1992, 28, 65-70.	1.2	9
229	Numb Expression Contributes to the Maintenance of an Undifferentiated State in Human Epidermis. Cell Transplantation, 2016, 25, 353-364.	1.2	9
230	Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. Critical Reviews in Oncology/Hematology, 2016, 106, 132-142.	2.0	9
231	Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. Journal of Cellular Physiology, 2017, 232, 2246-2252.	2.0	9
232	A moonshot approach toward the management of cancer patients in the COVID-19 time: what have we learned and what could the Italian network of cancer centers (Alliance Against Cancer, ACC) do after the pandemic wave?. Journal of Experimental and Clinical Cancer Research, 2020, 39, 109.	3.5	9
233	Two-Step Coimmunoprecipitation (TIP) Enables Efficient and Highly Selective Isolation of Native Protein Complexes. Molecular and Cellular Proteomics, 2018, 17, 993-1009.	2.5	8
234	The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition. Cancers, 2021, 13, 1957.	1.7	8

#	Article	IF	Citations
235	The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. Scientific Reports, 2021, 11, 13770.	1.6	8
236	Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. Oncotarget, 2017, 8, 108463-108479.	0.8	8
237	Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51. Oncogene, 2022, 41, 2196-2209.	2.6	8
238	Involvement of interferon regulatory factor-1 in monocyte CD95 expression and CD95-mediated apoptosis. Cell Death and Differentiation, 2003, 10, 615-617.	5.0	7
239	Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity. Haematologica, 2008, 93, 1899-1902.	1.7	7
240	Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine. Oncotarget, 2017, 8, 48534-48544.	0.8	7
241	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. Expert Opinion on Drug Discovery, 2013, 8, 1381-1397.	2.5	6
242	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. Scientific Reports, 2016, 6, 35121.	1.6	6
243	Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer. Journal of Translational Medicine, 2018, 16, 247.	1.8	6
244	Quantum dots for biomedical applications. Expert Opinion on Medical Diagnostics, 2008, 2, 315-322.	1.6	5
245	Functional Role of MicroRNAs in Prostate Cancer and Therapeutic Opportunities. Critical Reviews in Oncogenesis, 2013, 18, 303-316.	0.2	5
246	A predictive signature for therapy assignment and risk assessment in prostate cancer. Oncoscience, 2015, 2, 920-923.	0.9	5
247	The PU.1 transcription factor induces cyclin D2 expression in U937 cells. Leukemia, 2006, 20, 2208-2210.	3.3	4
248	How to Assess Drug Resistance in Cancer Stem Cells. Methods in Molecular Biology, 2018, 1692, 107-115.	0.4	4
249	Twoâ€Step Coâ€Immunoprecipitation (TIP). Current Protocols in Molecular Biology, 2019, 125, e80.	2.9	4
250	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel antiâ€HER2 agents in the real world setting. International Journal of Cancer, 2020, 146, 1917-1929.	2.3	4
251	Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e637-e641.	1.1	4
252	Dual Inhibition of Myc Transcription and PI3K Activity Effectively Targets Colorectal Cancer Stem Cells. Cancers, 2022, 14, 673.	1.7	4

#	Article	IF	Citations
253	Translating basic research in cancer patient care. Annali Dell'Istituto Superiore Di Sanita, 2011, 47, 64-71.	0.2	4
254	THE MIR-15A/MIR-16-1 CLUSTER CONTROLS PROSTATE CANCER PROGRESSION CONTROL BY TARGETING OF MULTIPLE ONCOGENIC ACTIVITIES. Journal of Urology, 2009, 181, 188-188.	0.2	3
255	Alleanza Contro il Cancro: The Accreditation System of the Excellence Network of Italian Cancer Centers in the Precision Medicine Era. Tumori, 2015, 101, S64-S66.	0.6	3
256	Colorectal cancer: towards new challenges and concepts of preventive healthcare. Ecancermedicalscience, 2017, 11, ed74.	0.6	3
257	Lipid and Glycolipid Mediators in CD95-Induced Apoptotic Signaling. Results and Problems in Cell Differentiation, 1999, 23, 65-76.	0.2	3
258	Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers. Tumori, 2013, 99, 293e-8e.	0.6	3
259	Epstein-Barr virus DNA is present both in CD10CD77 positive and negative subsets of human tonsillar lymphocytes. Cancer Letters, 1995, 89, 125-128.	3.2	2
260	Response to 'Thyrocytes â€" not innocent bystanders in autoimmune disease'. Nature Immunology, 2001, 2, 183-183.	7.0	2
261	Response to 'TH1 and TH2 cytokine control of thyrocyte survival in thyroid autoimmunity'. Nature Immunology, 2001, 2, 371-371.	7.0	2
262	International Accreditation of Cancer Centres of Italian Network of Alleanza Contro il Cancro: Introductory Remarks. Tumori, 2015, 101, S1-S1.	0.6	2
263	Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology. JCO Precision Oncology, 2018, 2, 1-16.	1.5	2
264	Approaching the Increasing Complexity of Non-small Cell Lung Cancer Taxonomy. Current Pharmaceutical Design, 2014, 20, 3973-3981.	0.9	2
265	Cancer Stem Cells. , 2011, , 151-168.		2
266	The Regina Elena National Cancer Institute Process of Accreditation according to the Standards of the Organisation of European Cancer Institutes. Tumori, 2015, 101, S51-S54.	0.6	1
267	Abstract 4316: hMENA11acontributes to HER3-mediated resistance to PI3K inhibitors in HER2 overexpressing breast cancer cells. , 2015, , .		1
268	Replication stress in colorectal cancer stem cells. Oncotarget, 2017, 8, 90606-90607.	0.8	1
269	Multicohort and crossâ€platform validation of a prognostic Wnt signature in colorectal cancer. Clinical and Translational Medicine, 2020, 10, e199.	1.7	1
270	Reprogramming: So simple, so complex. Cell Death and Differentiation, 2012, 19, 1253-1254.	5.0	0

#	Article	IF	Citations
271	Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia.. Blood, 2007, 110, 4307-4307.	0.6	0
272	Abstract 2925: Protein pathway activation mapping of the NCI60 cell line series: Discovery of lineage-independent protein biomarkers for drug sensitivity/resistance prediction. , 2011, , .		0
273	Abstract 3312: Protein activation pathway analysis of glioblastoma stem cells reveals potential novel biomarkers. , 2011, , .		0
274	Abstract 4911: Systems level network analysis of NCI60 cell lines by alignment of protein pathway activation modules with multiple -omic data fields and therapeutic response signatures. , 2012, , .		0
275	Abstract 883: Cell-based selection of RNA-aptamers to specifically target glioblastoma cancer stem cells. , 2012, , .		0
276	Abstract B5: A BMP7 variant inhibits angiogenesis in vitro and in vivo in part by downregulating VEGFR2 and FGFR1 expression in endothelial cells.. , 2013, , .		0
277	Translational impact of patient-derived glioblastoma tumorspheres.. Journal of Clinical Oncology, 2016, 34, 2025-2025.	0.8	0
278	Abstract 2484: Non-canonical Hedgehog/Gli1 signaling drives lung adenocarcinoma stem cells survival and its targeting inhibits CSC-derived tumors. , 2016, , .		0
279	Abstract LB-040: Establishment of a predictive patient-derived xenograft model for renal cell carcinoma. , 2016, , .		0
280	Abstract SY01-02: Targeting stem cell pathways in human cancer. , 2016, , .		0
281	Establishment of patient-derived renal cell carcinoma (RCC) models based on orthotopic xenografts (PDX) and cancer stem cell (CSC) isolation to provide prognostic and predictive information.. Journal of Clinical Oncology, 2017, 35, e16055-e16055.	0.8	0